Lumos Pharma, Inc. / Fundamentals
Income statement
- Net revenue
€1.89M - Cost of goods sold
€18.88K - Gross profit
€1.87M - SG&A expenses
€13.58M - R&D expenses
€19.47M - EBITDA
-€31.15M - D&A
€18.88K - EBIT
-€31.17M - Interest expenses
€591.16K - EBT
-€29.96M - Tax expenses
€587.49K - Net income
-€29.96M
Cash flow statement
- Net deferred tax
€136.42K - Non-cash items
€2.31M - Changes in working capital
€1.33M - Operating cash flow
-€27.18M - Capex
€11.33M - Other investing cash flow
€5.30M - Net investing cash flow
€6.15M - Total cash dividends paid
€0.00 - Issuance of common stock
€646.07K - Debt repayment
€0.00 - Other financing cash flow
-€2.57K - Net financing cash flow
€2.11M - Foreign exchange effects
€7.51M - Net change in cash
-€18.91M - Cash at end of period
€11.60M - Free cash flow
-€15.85M
Balance sheet
- Cash and cash equivalents
€11.60M - Cash and short-term investments
€11.60M - Total receivables
€149.29K - Inventory
€0.00 - Other current assets
€3.07M - Total current assets
€14.82M - Property, plant & equipment
€160.45K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€160.45K - Total assets
€14.98M - Accounts payable
€1.25M - Short-term debt
€111.54K - Other current liabilities
€4.22M - Total current liabilities
€5.58M - Long-term debt
€36.04K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€5.15M - Total non-current liabilities
€5.18M - Total liabilities
€10.77M - Common stock
€73.79K - Retained earnings
-€160.43M - Other equity
€0.00 - Total equity
€4.22M - Total liabilities and shareholders' equity
€14.98M
Company information
- Market capitalization
€32.02M - Employees
30 - Enterprise Value
€24.19M
Company ratios
- Gross margin
-
99.0% Much better than peer group: -256.0% - EBITDA margin
-
-1,646.6% Much better than peer group: -7,621.7% - EBIT margin
-
-1,647.6% Much better than peer group: -10,547.3% - EBT margin
-
-1,583.5% Much better than peer group: -6,750.0% - Net margin
-
-1,583.5% Much better than peer group: -7,134.9% - ROE
-
-710.5% Much worse than peer group: -194.8% - ROA
-
-200.0% Much better than peer group: -403.2% - Asset turnover
-
12.6% Much worse than peer group: 934.9% - FCF margin
-
-2,035.3% Much better than peer group: -7,771.2% - FCF yield
-120.3% - Efficiency ratio
1,746.6% - Net sales per employee
-
€63.06K - Net income per employee
-
-€998.60K